Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2022-12-09 00:00:00 ET · period of report 2022-12-07 · accession 0001415889-22-012301 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-12-09	2022-12-07	CLDX	KELER TIBOR	CSO, EXECUTIVE VP	S - Sale+OE	$36.93	-16.9K	7,357	-70%	-$622.6K
D	2022-12-09	2022-12-07	CLDX	KELER TIBOR	CSO, EXECUTIVE VP	M - OptEx	$2.78	+16.9K	24.2K	+229%	+$46.9K
D	2022-12-09	2022-12-07	CLDX	KELER TIBOR	CSO, EXECUTIVE VP	M - OptEx	$0.00	-16.9K	43.1K	-28%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, par value $0.001 per share	2022-12-07	S	D	16,860	$36.93	7,357	D	—	—	(F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
2	Common	Common Stock, par value $0.001 per share	2022-12-07	M	A	16,860	$2.78	24,217	D	—	—
3	Derivative	Incentive Stock Option (right to buy)	2022-12-07	M	D	16,860	$0.00	43,140	D	$2.78 · — to 2029-06-19	16,860 Common Stock	(F2) 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.